HomeCompareGILD vs SYF

GILD vs SYF: Dividend Comparison 2026

GILD yields 2.34% · SYF yields 1.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SYF wins by $61.2K in total portfolio value· pulled ahead in Year 2
10 years
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →
SYF
SYF
● Live price
1.82%
Share price
$66.01
Annual div
$1.20
5Y div CAGR
49.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$90.4K
Annual income
$30,601.07
Full SYF calculator →

Portfolio growth — GILD vs SYF

📍 SYF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGILDSYF
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GILD + SYF cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GILD pays
SYF pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
SYF
Annual income on $10K today (after 15% tax)
$154.52/yr
After 10yr DRIP, annual income (after tax)
$26,010.91/yr
At 15% tax rate, SYF beats the other by $24,638.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GILD + SYF for your $10,000?

GILD: 50%SYF: 50%
100% SYF50/50100% GILD
Portfolio after 10yr
$59.8K
Annual income
$16,107.99/yr
Blended yield
26.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GILD right now

GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
SYF
Analyst Ratings
26
Buy
14
Hold
1
Strong
Consensus: Buy
Price Target
$90.08
+36.5% upside vs current
Range: $81.00 — $100.00
Altman Z
0.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GILD buys
0
SYF buys
0
No recent congressional trades found for GILD or SYF in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGILDSYF
Forward yield2.34%1.82%
Annual dividend / share$3.19$1.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17.3%49.4%
Portfolio after 10y$29.1K$90.4K
Annual income after 10y$1,614.90$30,601.07
Total dividends collected$7.6K$64.6K
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusBuyBuy
Analyst price target$158.71$90.08

Year-by-year: GILD vs SYF ($10,000, DRIP)

YearGILD PortfolioGILD Income/yrSYF PortfolioSYF Income/yrGap
1$10,974$274.45$10,972$271.60+$2.00GILD
2← crossover$12,073$330.19$12,156$416.06$83.00SYF
3$13,316$398.20$13,650$643.63$334.00SYF
4$14,730$481.49$15,615$1,009.16$885.00SYF
5$16,345$583.87$18,320$1,611.86$2.0KSYF
6$18,199$710.26$22,243$2,640.44$4.0KSYF
7$20,340$866.96$28,276$4,476.19$7.9KSYF
8$22,826$1,062.22$38,200$7,945.19$15.4KSYF
9$25,731$1,306.80$55,862$14,987.29$30.1KSYF
10$29,147$1,614.90$90,373$30,601.07$61.2KSYF

GILD vs SYF: Complete Analysis 2026

GILDHealthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →

SYFFinancials

Synchrony Financial, together with its subsidiaries, operates as a consumer financial services company in the United States. It provides credit products, such as credit cards, commercial credit products, and consumer installment loans. The company also offers private label credit cards, dual cards, co-brand and general purpose credit cards, short- and long-term installment loans, and consumer banking products; and deposit products, including certificates of deposit, individual retirement accounts, money market accounts, and savings accounts to retail and commercial customers, as well as accepts deposits through third-party securities brokerage firms. In addition, it provides debt cancellation products to its credit card customers through online, mobile, and direct mail; healthcare payments and financing solutions under the CareCredit, Pets Best, and Walgreens brands; payments and financing solutions in the apparel, specialty retail, outdoor, music, and luxury industries; and point-of-sale consumer financing for audiology products and dental services. The company offers its credit products through programs established with a group of national and regional retailers, local merchants, manufacturers, buying groups, industry associations, and healthcare service providers; and deposit products through various channels, such as digital and print. It serves digital, health and wellness, retail, home, auto, powersports, jewelry, pets, and other industries. Synchrony Financial was founded in 1932 and is headquartered in Stamford, Connecticut.

Full SYF Calculator →
📬

Get this GILD vs SYF comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GILD vs SCHDGILD vs JEPIGILD vs OGILD vs KOGILD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.